BCL2 and lymphoma: Due to the fact that concurrent MYC and BCL-2 rearrangements enrich for a patient’s population characterized by refractoriness to standard anthracycline-based chemotherapy, these lymphomas are now classified as a separate disease entity (HG-BCL w/DH) [15] and currently treated with more intensive chemotherapy regimens, representing a major unmet need in lymphoma therapy [16, 17].